Key insights from therapeutic drug monitoring in Crohn’s disease patients

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.
Original languageEnglish
JournalExpert Opinion on Drug Metabolism and Toxicology
DOIs
Publication statusPublished - 2019

Cite this

@article{afc8711d957f4b188fc6252a1b26252b,
title = "Key insights from therapeutic drug monitoring in Crohn’s disease patients",
abstract = "Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.",
author = "Seinen, {Margien L.} and {de Boer}, {Nanne K.} and {van Bodegraven}, {Adriaan A.}",
year = "2019",
doi = "10.1080/17425255.2019.1597054",
language = "English",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Key insights from therapeutic drug monitoring in Crohn’s disease patients

AU - Seinen, Margien L.

AU - de Boer, Nanne K.

AU - van Bodegraven, Adriaan A.

PY - 2019

Y1 - 2019

N2 - Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.

AB - Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064677132&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30892105

U2 - 10.1080/17425255.2019.1597054

DO - 10.1080/17425255.2019.1597054

M3 - Article

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

ER -